Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-01
2005-02-01
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S249000, C514S252200, C514S252130, C514S252160, C514S253040, C514S254100, C514S263230, C514S266400, C514S274000, C514S326000, C514S343000, C514S422000, C544S264000, C544S265000, C544S274000, C544S276000, C544S277000, C544S295000, C544S354000, C544S362000, C544S379000, C546S208000, C546S278400, C548S517000, C549S013000, C549S028000, C549S063000, C549S065000, C549S419000, C549S424000, C549S425000, C549S426000, C549S479000, C549S480000, C549S483000, C549S487000
Reexamination Certificate
active
06849660
ABSTRACT:
Provided are antibacterial compounds having Formula I:In such compositions, X is O or S; Y is CH2; n is0or1. One of R1and R1′is —C(O)NR5R5′, —C(O)—Q—NR5R5′, —CH2NR5R5′or —S(O)2NR5R5′and the other is H or R3. One of R2and R2′is —NHC(O)R6or —NHS(O)2R6and the other is H or R4. Q is an amino acid or peptide. R3is H, halogen, —NR5R5′or —NHC(O)R6; and R4is selected from the group consisting of H, halogen, hydroxyl, amino, carboxyl, alkyl, alkenyl and alkynyl. R5is selected from the group consisting of H, alkyl, alkenyl or alkynyl optionally substituted with halogen, OH, amino, amidinyl, guanidinyl, urea, alkyl, carboxyl, oxo, carboxamide; R5′is H or R5and R5′together form a 5-16 member heterocycle optionally substituted with halogen, OH, amino, alkyl, carboxyl, carbonyl or carboxamide. R6is selected from the group consisting of H; amino; alkyl, alkenyl or alkynyl, each optionally substituted with halogen, amino, amidinyl, guanidinyl, urea, carboxyl or carboxamide; a 5-16 member carbocycle or heterocycle; and a 5-16 member heterocycle-substituted alkyl or carbocycle-substituted alkyl, wherein said carbocycle and heterocycle are optionally substituted with halogen, OH, amino, alkyl, carboxyl, oxo or carboxamide.
REFERENCES:
patent: WO 9610559 (1996-04-01), None
A.L. Lehninger, Principles of Biochemistry, Worth Publishers, New York, 1985; ISBN 0-87901-136-X.*
J.S. Davis (Ed.), Amino Aciids and Peptides, Chapman and Hall, New York, 1985; ISBN 0-412-26950-3.*
Marchbanks, C. et al., “New Fluoroquinolones”,Hospital Therapy, 1988, 7, 18-19, 23-27, 31, and 34-35.
Parry, M., “Pharmacology and Clinical Uses of Quinolone Antibiotic”,Medical Times, 1988, 116(12), 39-45 and 19.
Shah, P., “Quinolones”,Prog. Drug Res., 1987, 31, 243-256.
Ehmer et al., “Development of a Simple and Rapid Assay for the Evaluation of Inhibitors of Human 17.alpha.-hydroxylase-C17,20-lyase (P450c17), by Coexpression of PH450c17 with NADPH-cytochrome-P450-reductase inEscherichia coli,”Journal of Steroid Biochemistry&Molecular Biology, Dec. 2000, 75,(1), 57-63.
Gravel et al., “Resin-to-Resin Suzuki Coupling of Solid Supported Arylboronic Acids,”Journal of Combinatorial Chemistry, May 2000, 2(3), 228-231.
Search Report issued in International Application No. PCT/US01/24067, Date of Mailing: Apr. 3, 2002.
Copy of PCT Written Opinion dated Feb. 24, 2003 (PCT/US01/24067).
Muller, et al., “Polyamide oligomers from epsilon-aminocaproic acid and isomeric aminophenylcarboxylic acids,”J. for Praktische Chemie, 1970, 312(1), 78-89.
Jefferson Elizabeth
Swayze Eric
Coleman Brenda
ISIS Pharmaceuticals Inc.
O'Connor Cozen
Straher Michael P.
LandOfFree
Antimicrobial biaryl compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antimicrobial biaryl compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antimicrobial biaryl compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3460642